Cancer patients' expectations when undergoing extensive molecular diagnostics-A qualitative study

Area of Science:

• Oncology
• Genomics
• Patient Experience Research

Background:

• Precision cancer medicine (PCM) utilizes molecular characteristics to tailor cancer therapy.
• Despite advances, PCM faces challenges, and patient expectations for personal benefit from extensive molecular diagnostics (MD) are not always aligned with clinical realities.
• Understanding patient experiences is vital for effective support.

Purpose of the Study:

• To explore the expectations of advanced-stage cancer patients undergoing extensive molecular diagnostics (MD).
• To identify patient hopes and perceived benefits associated with MD participation.
• To inform healthcare professionals on providing better patient support.

Main Methods:

• Semi-structured interviews were conducted with 30 advanced-stage cancer patients at two German Comprehensive Cancer Centers.
• The study involved extensive, research-oriented MD, including whole-genome and panel sequencing.
• Thematic content analysis was used to code interview transcripts, supplemented by questionnaires on patient characteristics and distress.

Main Results:

• Patients expected improved treatment, contributions to research, and deeper insight into their cancer.
• Participation in MD fostered feelings of individual appreciation and provided a basis for hope.
• Patients reported feeling more "personalized" care and a greater sense of control.

Conclusions:

• Extensive molecular diagnostics can enhance patients' sense of personalized care and control.
• Healthcare professionals must provide comprehensive information and empathetic support to align patient expectations with clinical outcomes.
• Balancing patient hopes with the realities of clinical benefit is essential for effective PCM support.